-
Future Markets Research Releases Commentary on NurExone Biologic Inc, An Emerging Leader in The Exosomal Treatment of Spinal Cord Injury
Future Markets Research Releases Commentary on NurExone Biologic Inc, An Emerging Leader in The Exosomal Treatment of Spinal Cord Injury
Share
LONDON--(BUSINESS WIRE)--The Future Markets Research Tank (FMRT) is proud to release market commentary on NurExone Biologic (TSXV: NRX) (FSE: J90), an innovative biotechnology company poised to disrupt the spinal cord injury treatment industry and the exosome research landscape. To read the full report click here, or follow the link: https://bit.ly/3UW9TzC
Key Insights:
- Each year, hundreds of thousands of people suffer from spinal cord injury. In addition, poor medical care and the lack of availability of effective treatments contribute to an increase in SCI patient mortality and disability.
- With rising numbers of workplace accidents, road accidents, and other medical conditions, the global SCI therapeutics market is anticipated to grow at a Compound annual growth rate (CAGR) of 17.84% to reach US$9.61 billion by 2028. There is a pressing need to create novel therapeutics to treat SCI due to the exorbitant cost of spinal surgery procedures and related healthcare costs.
- In parallel, the global exosome market is estimated to grow at a CAGR of more than 34% between 2022 and 2030, reaching a market value of around USD 2,273 million by 20303
- NurExone Biologic is an exciting company that sits at the forefront of these two fast growing arenas. With their unique ExoTherapies, NurExone is making significant advancements towards becoming a market leader in exosome-based treatment for acute spinal cord injuries. As the company grows, it has announced numerous strategic initiatives, such as plans to expand its intellectual property portfolio and partnerships for advanced research.
- Moreover, positive preliminary findings prove the company's potential and distinguish itself as an emerging exosome leader with an intriguing biotechnology portfolio and offering. As the company continues innovating and achieving meaningful milestones, they are well positioned to become a leading biotech company and central player in both the exosome and the spinal cord treatment arenas.
To read the full report click here, or follow the link: https://bit.ly/3UW9TzC
Contacts
Ronald Kaufman
Future Markets Research Tank (FMRT)
ronald@futuremarketsresearch.com
More News From Future Markets Research Tank
Future Markets Research Report: NOA Lithium Positioned to Capitalize on Critical Lithium Supply Gap Amid Surging Global Demand
NEW YORK--(BUSINESS WIRE)--Future Markets Research Releases a Report on Noa Lithium Brines Inc (TSXV: NOAL)*. NOA Lithium operates at the nexus of several transformative global trends, including the clean energy transition, electric vehicle adoption, and grid-scale energy storage. The company's strategic portfolio of over 140,000 hectares across three prospective salars in Argentina's Salta Province positions it among the most promising lithium developers in the industry. With its recent resour...
PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises
LONDON--(BUSINESS WIRE)--PESG Research Releases an Market Update Report on Silexion Therapeutics (NASDAQ: SLXN). The precision oncology sector has rapidly evolved into one of the most dynamic areas of cancer treatment innovation. Among the key players pioneering novel approaches is Silexion Therapeutics, a clinical-stage biotechnology company focused on RNA interference (RNAi) therapies for KRAS-driven cancers—one of the most prevalent and historically “undruggable” oncogenic drivers. Silexion’...
Future Markets Research Releases Report on Actelis Networks: A Key Player Amidst Smart City Growth and Rising Infrastructure Cyber Risks
LONDON--(BUSINESS WIRE)--Actelis operates at the intersection of rapidly growing industries, including smart cities, cybersecurity, and critical infrastructure modernization. The company’s hybrid-fiber technology, which combines the speed and reliability of fiber-grade connectivity with the cost-effectiveness of leveraging existing copper infrastructure, has proven indispensable for cities and government entities seeking efficient solutions for upgrading aging networks. In 2024, Actelis introdu...
